Laura Durcan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Laura Durcan has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Arlene M. A. Glasgow
Lung Biology Group, Department of Clinical Microbiology, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland
1 shared publication - Catherine M. Greene
RCSI University of Medicine and Health Sciences
1 shared publication Grainne Murphy
Cork University Hospital, Cork, Ireland
1 shared publication- Irene K. Oglesby
Department of Medicine, Royal College of Surgeons in Ireland Education and Research Centre, Beaumont Hospital , Beaumont, Dublin
1 shared publication - Jake Michael McDonnell
National Spine Injuries Unit, Mater Misericordiae University Hospital, Dublin, Ireland
1 shared publication - Justin Wormald
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX1 2DJ, UK
1 shared publication
Latest Publications
- 7 May 2026
- Published by Elsevier in The Lancet
- Vol. 407 (10541) , 1761-1763
Could enpatoran add to our therapeutic toolbox in SLE?
- 7 May 2026
- Published by Elsevier in The Lancet
- Vol. 407 (10541) , 1761-1763
Could enpatoran add to our therapeutic toolbox in SLE?
- Open Access
Botulinum Toxin for the Treatment of Raynaud’s Conditions of the Hand: Clinical Practice Updates and Future Directions
Raynaud’s conditions of the hand, referred to commonly as Raynaud’s phenomenon, both primary and secondary, represents a spectrum of disorders affecting the digits, characterised by recurrent episodes of vasospasm that result in a triad of symptoms: pain, pallor, and cyanosis. Various therapies, ranging from conservative hand therapy techniques to surgical sympathectomy, have been explored with inconsistent results. Recently, the local administration of botulinum toxin type-A (BTX-A) has re-emerged as a treatment option for this condition. This review delves into the mechanistic pathways of BTX-A therapy, optimal dosing concentrations, administration techniques, and its safety profile. A critical analysis of published studies to date demonstrates varied clinical efficacy of BTX-A in Raynaud’s conditions based on patient-reported outcome measures and objective measures of outcomes assessment. Thus, in order to accurately assess the clinical effectiveness of BTX-A in future robust studies, this review emphasises the importance of streamlining patient selection to minimise heterogeneity in disease severity, optimising recruitment to ensure adequate statistical power, and establishing sensitive outcome measures to monitor response and discern treatment efficacy. Additionally, addressing concerns such as minimising antibody resistance, extending the duration of treatment effects on tissues, and exploring new modalities to assess hand perfusion will be focal points for future research and BTX-A drug development.
Open AccessBotulinum Toxin for the Treatment of Raynaud’s Conditions of the Hand: Clinical Practice Updates and Future Directions
Raynaud’s conditions of the hand, referred to commonly as Raynaud’s phenomenon, both primary and secondary, represents a spectrum of disorders affecting the digits, characterised by recurrent episodes of vasospasm that result in a triad of symptoms: pain, pallor, and cyanosis. Various therapies, ranging from conservative hand therapy techniques to surgical sympathectomy, have been explored with inconsistent results. Recently, the local administration of botulinum toxin type-A (BTX-A) has re-emerged as a treatment option for this condition. This review delves into the mechanistic pathways of BTX-A therapy, optimal dosing concentrations, administration techniques, and its safety profile. A critical analysis of published studies to date demonstrates varied clinical efficacy of BTX-A in Raynaud’s conditions based on patient-reported outcome measures and objective measures of outcomes assessment. Thus, in order to accurately assess the clinical effectiveness of BTX-A in future robust studies, this review emphasises the importance of streamlining patient selection to minimise heterogeneity in disease severity, optimising recruitment to ensure adequate statistical power, and establishing sensitive outcome measures to monitor response and discern treatment efficacy. Additionally, addressing concerns such as minimising antibody resistance, extending the duration of treatment effects on tissues, and exploring new modalities to assess hand perfusion will be focal points for future research and BTX-A drug development.
- Open Access
- 24 November 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (12) , 3030
Sexual Dimorphism in Interstitial Lung Disease
Interstitial lung diseases (ILD) are a group of heterogeneous progressive pulmonary disorders, characterised by tissue remodelling and/or fibrotic scarring of the lung parenchyma. ILD patients experience lung function decline with progressive symptoms, poor response to treatment, reduced quality of life and high mortality. ILD can be idiopathic or associated with systemic or connective tissue diseases (CTD) but idiopathic pulmonary fibrosis (IPF) is the most common form. While IPF has a male predominance, women are affected more greatly by CTD and therefore associated ILDs. The mechanisms behind biological sex differences in these progressive lung diseases remain unclear. However, differences in environmental exposures, variable expression of X-chromosome related inflammatory genes and sex hormones play a role. Here, we will outline sex-related differences in the incidence, progression and mechanisms of action of these diseases and discuss existing and novel cellular and pre-clinical studies. Furthermore, we will highlight how sex-differences are not adequately considered in pre-clinical disease models, how gender bias exists in clinical diagnosis and how women are underrepresented in clinical trials. Future action on these observations will hopefully shed light on the role of biological sex in disease development, identify potential targets for intervention and increase female participant numbers in clinical trials.
- 24 November 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (12) , 3030
Open AccessSexual Dimorphism in Interstitial Lung Disease
Interstitial lung diseases (ILD) are a group of heterogeneous progressive pulmonary disorders, characterised by tissue remodelling and/or fibrotic scarring of the lung parenchyma. ILD patients experience lung function decline with progressive symptoms, poor response to treatment, reduced quality of life and high mortality. ILD can be idiopathic or associated with systemic or connective tissue diseases (CTD) but idiopathic pulmonary fibrosis (IPF) is the most common form. While IPF has a male predominance, women are affected more greatly by CTD and therefore associated ILDs. The mechanisms behind biological sex differences in these progressive lung diseases remain unclear. However, differences in environmental exposures, variable expression of X-chromosome related inflammatory genes and sex hormones play a role. Here, we will outline sex-related differences in the incidence, progression and mechanisms of action of these diseases and discuss existing and novel cellular and pre-clinical studies. Furthermore, we will highlight how sex-differences are not adequately considered in pre-clinical disease models, how gender bias exists in clinical diagnosis and how women are underrepresented in clinical trials. Future action on these observations will hopefully shed light on the role of biological sex in disease development, identify potential targets for intervention and increase female participant numbers in clinical trials.
- 1 October 2020
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 50 (5) , 1081-1086
The clinical and serological associations of hypocomplementemia in a longitudinal sle cohort
- 1 October 2020
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 50 (5) , 1081-1086
The clinical and serological associations of hypocomplementemia in a longitudinal sle cohort
- Top Cited Papers
- 1 June 2019
- Published by Elsevier in The Lancet
- Vol. 393 (10188) , 2332-2343
Management strategies and future directions for systemic lupus erythematosus in adults
- 1 June 2019
- Published by Elsevier in The Lancet
- Vol. 393 (10188) , 2332-2343
Top Cited PapersManagement strategies and future directions for systemic lupus erythematosus in adults